NMPA Approves Keverprazan for Duodenal Ulcers and Reflux Esophagitis
The National Medical Products Administration (NMPA) has granted approval to Jiangsu Carephar Pharmaceutical Co., Ltd’s...
Drug
AIM Vaccine Gains Approvals for COVID-19 mRNA Vaccine Trials in Pakistan
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving separate approvals in Pakistan to...
Innovent Biologics Initiates Phase III CLEAR Study for Picankibart in Psoriasis
China-based Innovent Biologics (HKG: 1801) has announced the first subject dosing in the Phase III...
Frontera Therapeutics Initiates FT-002 Clinical Study for X-Linked Retinitis Pigmentosa
Sino-US gene therapy specialist Frontera Therapeutics has announced the first patient dosing in a clinical...
Kanghong’s KH617 Receives Orphan Drug Designation for Glioblastoma
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving an Orphan Drug...
Luye Pharma’s BA2101 Begins Phase I Clinical Trial for Allergic Diseases
China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase...
CDE Accepts Clinical Trial Filing for Ranok’s First-in-Class BRD4 Degradation Drug RNK05047
The Center for Drug Evaluation (CDE) website indicates that a clinical trial filing for RNK05047,...
Junshi Biosciences and Coherus Report Positive JUPITER-02 Trial Results for NPC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) and its US partner Coherus BioSciences...
Hengrui Pharmaceuticals Gains NMPA Approval for SHR-A1921 Clinical Study
Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving the go-ahead from the National Medical Products...
Zelgen’s ZG2001 and ZG0895 Clinical Trials Approved by NMPA
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that separate clinical trial filings for...
Innovent Biologics Initiates Phase II Study for IBI311 in Thyroid-Associated Ophthalmopathy
China-based Innovent Biologics Inc., (HKG: 1801) has announced the first patient dosing in a Phase...
Kangtai Biological Begins Phase I Trial for Tetravalent Influenza Vaccine
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the first subject enrollment...
Jiangsu Recbio Completes First Tranche Enrollment for Shingles Vaccine REC610
China-based Jiangsu Recbio Technology Co., Ltd has announced the completion of the first tranche of...
Beijing Wantai Initiates Phase I Study for 20-Valent Pneumonia Vaccine
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced the initiation and...
Gracell Biotechnologies Gains IND Approval for GC012F in China
Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the Center for Drug...
RemeGen Gains NMPA Approval for RC48 and Pyrotinib Clinical Study
China-based RemeGen Ltd (HKG: 9995) has announced receiving the go-ahead from the National Medical Products...
Clover Biopharmaceuticals Administers First Dose of COVID-19 Vaccine SCB-2019 in Zhejiang
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced the first jab of its COVID-19 vaccine...
CSPC Pharmaceutical Licenses ADC SYS6002 to Corbus Pharmaceuticals
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced a licensing agreement with Massachusetts-based Corbus...
Luye Pharma Initiates Phase I Study for BA1106, a CD25 Monoclonal Antibody
China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase...
Zelgen’s ZGGS15 Accepted for NMPA Review as First Global BsAb Filing
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that a clinical trial filing for...